Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

Adaptimmune Therapeutics plc. (8/2/18). "Press Release: Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update". Philadeliphia, PA & Oxford.

Organisations Organisation Adaptimmune Therapeutics plc (Nasdaq: ADAP)
  Group Adaptimmune (Group)
  Organisation 2 GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Group GlaxoSmithKline (GSK) (Group)
Products Product MAGE-A10 SPEAR™ T-cell therapy
  Product 2 NY-ESO SPEAR® T-cell therapy
Index term Index term GSK–Adaptimmune: cancer immunotherapy, 201406– strategic collab up to $350m using TCR engineering techn for cell-based therapies incl NY-ESO-1
Person Person Noble, James (Adaptimmune CEO before MediGene 200609–200809 before Avidex)
     


   
Record changed: 2018-08-11

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for Adaptimmune (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top